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FREQUENTLY ASKED QUESTIONS 
Publications 
This information brochure has been produced by the EMCDDA to provide 
answers to the most commonly asked questions on the Reitox network of national 
focal points and more broadly on national drugs observatories. Compiled over 
several years, it is a reference tool for both EU Member States and countries 
further afield on the network, its members, its role and development. 
About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the 
hub of drug -related information in Europe. Its mission is to provide the EU and its 
Member States with ‘factual, objective, reliable and comparable information’ on 
drugs, drug addiction and their consequences. Established in 1993, it opened its 
doors in Lisbon in 1995 and is one of the EU’s decentralised agencies. With a 
100 -strong multidisciplinary team, the agency offers policymakers the evidence 
base they need for drawing up drug laws and strategies. It also helps professionals 
and researchers pinpoint best practice and new areas for analysis. As well as 
gathering information on the demand and reduction of the demand for drugs, the 
agency in recent years has extended its monitoring and reporting on drug supply, 
supply reduction and illicit drug markets. 
www.emcdda.europa.eu
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One of the core tasks of the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) is to collect, analyse and disseminate information on drugs and drug addiction in 
Europe. In order to fulfil the above, the EMCDDA works closely with the Reitox network.
This publication brings together some of the most frequently asked questions about Reitox, how it 
functions, who are Reitox members and how to participate in the network. Further details can be 
found via the websites and other links provided at the end of this brochure.
1. What is Reitox?
Reitox is the European information network on drugs and drug addiction created at the same 
time as the European Monitoring Centre for Drugs and Drug Addiction. The first meeting of Reitox 
members was held in 1995. The abbreviation ‘Reitox’ stands for the French ‘Réseau Européen 
d´Information sur les Drogues et les Toxicomanies’. 
The working language of the network is English.
2. Who are members of the Reitox network?
Members of the Reitox network are designated national institutions or agencies responsible for 
data collection and reporting on drugs and drug addiction. These institutions are called ‘national 
focal points’ or ‘national drug observatories’. The Regulation governing the EMCDDA’S work 
requires that each EU Member State or other country participating in the work of the Centre 
shall establish or designate one national focal point. This designated national focal point then 
becomes a member of the network, which currently includes each of the 27 EU Member States 
plus Croatia, Turkey, Norway and the European Commission. 
3. What is the Reitox network’s main mission?
Reitox directly contributes to the EMCDDA’s core task of collecting and reporting consistent, 
harmonised and standardised information on the drug phenomenon across Europe. 
Reitox links national drug information systems and is the main way in which the EMCDDA 
exchanges data and methodological information on drugs and drug addiction in Europe.  
Data collected through the Reitox network are also utilised to monitor and support the evaluation 
of the outcomes of the EU drugs action plans, within its drug strategy. Furthermore, the data help 
guide EU drug policies and develop recommendations for appropriate national responses for 
organising treatment, prevention and harm reduction activities. The information gathered through 
the EU Early warning system for new psychoactive substances implemented in cooperation with 
the network makes it possible to adopt decisions  for putting these under control within the EU. 
4. Is there a difference between a national focal point and  
a national drugs observatory?
A national drugs observatory (NDO) is a generic term for an organisation that provides 
its country with factual, objective and comparable information concerning drugs and drug 
addiction and their consequences. In the European Union context, ‘national focal points’ 
(NFPs) are effectively national drugs observatories. The term comes from Regulation (EC) 
No 1920/2006 of the European Parliament and the Council of 12 December 2006 on the 
European Monitoring Centre for Drugs and Drug Addiction and is used in the EU drugs action 
plans to describe a set of roles and functions vis -à -vis the EU and the EMCDDA.
5. What are the functions of Reitox national focal points  
at European level? 
The national focal points are the cornerstone of the European drug monitoring and reporting 
system. On an annual basis, a NFP should collect information and produce comparable and 
scientifically sound data on a national drug situation which will feed into monitoring the situation 
across Europe. 
The NFPs also help improve data collection methodologies and tools, and develop relevant 
guidelines for their implementation. 
In addition, the NFPs participate in the Early warning system and report to the EMCDDA on new 
trends in the use of existing psychoactive substances and/or new consumption patterns involving 
combinations of psychoactive substances which pose a potential public health risk. 
However, in many cases the role of NFPs goes beyond their reporting obligations to the 
EMCDDA and they also produce information to fulfil their country’s reporting obligations to other 
supranational and international monitoring and drug -control programmes.
The EMCDDA also requests the technical support of NFPs in the production of its different 
products and publications in national languages. 
6. What are the functions of Reitox national focal points  
at national level?
The three core functions of a national focal point are:
•	 data	collection	and	monitoring;
•	 analysis	and	interpretation	of	data	collected;
•	 reporting	and	dissemination	of	the	results	at	national	level.
These functions are usually carried out by the NFP in conjunction with other national institutions 
and experts forming a national drug information network coordinated by the NFP. 
Moreover, each country, which is solely responsible for setting up a NFP may also, depending 
on resources and data and expertise available at national level, expand the NFP’s mandate and 
tasks in order to meet national needs. 
The Reitox national focal points are asked to disseminate knowledge and best practice produced 
at European level and relevant for national needs to the extended community of professionals 
involved with drugs and drug addiction. They also support the broad dissemination of EMCDDA 
products and publications at national level. 
7. How is Reitox managed?
Daily management of the network is entrusted to the EMCDDA’s Reitox and international 
cooperation unit. Twice a year, the EMCDDA organises meetings for the Heads of national 
focal points to discuss and endorse data collection tools, reporting requirements for the 
upcoming reporting cycle and to further develop and consolidate the network and its 
members. The EMCDDA also maintains a Reitox extranet where it shares most up -to -date 
information on the EMCDDA’s activities, reporting requirements and also training opportunities 
for Reitox members.
The	network	has	a	Spokesperson	and	a	deputy;	both	are	elected	by	the	Heads	of	the	
NFPs. The Spokesperson has observer status on the EMCDDA’s Management Board, 
which is the EMCDDA’s main governing body, as well as on the EMCDDA’s Scientific 
Committee. This ensures that the network members are aware of the agency’s main 
strategic and scientific developments and that the Reitox network contributes to its 
decision -making process.
The Cyprus national focal point maintains an interactive, web -based Reitox Forum independent 
from the EMCDDA, to encourage information exchange and cooperation among the national 
focal points (for subscription and details, please see www.reitoxforum.eu). 
8. How should a national focal point be structured? 
There is no single model for how to organise and where to place a NFP, however national 
authorities must ensure that their NFP can collect and analyse data on the basis of guidelines 
adopted by the EMCDDA. 
The structure of a NFP largely depends on how decision -making is organised in a particular 
country. The NFP can be placed within a national drugs coordination body or under a 
government department, or located in one of the ministries. In many cases, the decision is 
taken to place the NFP in the Ministry of Health or the Ministry of the Interior, Home Affairs or 
National Security or their subordinate institutions, since drug -related data collection is a part 
of their regular activities. A university or a non -governmental organisation can also act as a 
national focal point. 
When discussing where to place the NFP, the main aspect to consider is how it will effectively 
fulfil its role and functions. The NFP has to maintain an independent status in order to report 
scientifically sound and credible information.                 
9. What types of information should Reitox members  
provide to the EMCDDA and when?
The European drug monitoring system is structured to cover two main areas: monitoring the 
situation and monitoring responses. 
•		The	monitoring	of	the	situation	is	based	on	five	key	epidemiological	indicators:	general	
population	surveys	and	youth	surveys;	problem	drug	use;	treatment	demand	indicator;	 
drug -related deaths and drug -related infectious diseases. 
•		Monitoring	responses	is	structured	around:	collection	of	best	practice;	demand	reduction;	
interventions	in	the	criminal	justice	system	and	national	strategies;	coordination	mechanisms	
and legislation.
The monitoring system implies the collection of both quantitative data and qualitative information 
using three different types of standardised data collection and reporting tools:
•		standard	tables	for	quantitative	data	collection,	reported	to	the	EMCDDA	every	year;
•		structured	questionnaires	for	qualitative	information,	essentially	monitoring	responses,	
reported	to	the	EMCDDA	every	year;
•		guidelines	for	writing	the	national	report	on	‘new	developments,	trends	and	in	‑depth	
information’. The national report provides contextual information and complements the figures 
reported through the other templates. The national report is also due every year.
10. How many staff members should work in a national focal point 
and what qualifications do they need?
The number of staff and their qualifications are closely linked to a national focal point’s role and 
functions. Given the range of tasks of a NFP, it must have at least a manager or coordinator 
(usually referred to as the Head). It is desirable that the professional competence of such a 
person allows him/her to effectively discuss issues related to drug -related data collection at 
national and European level. Practice shows that the Head of the focal point should have strong 
general management, communication and networking skills. 
Ideally, the competences of additional staff will mirror the wide range of subject areas covered 
by the NFP mandate. Therefore, the scientific competence of personnel should ideally cover 
fields such as: epidemiology, social sciences (sociology, psychology), toxicology, statistics, and 
criminology and drug policy. Countries with very limited resources might start with a one -person 
national focal point: if this is the case, some core functions in data collection, analysis and 
reporting should be delegated to external partners (e.g. a university). 
Last but not least, all staff members should ideally be fluent in English, as this is the working 
language of the Reitox network.
11. How are Reitox national focal points financed? 
The appointment, setting up, functioning and maintenance of a national focal point is the 
responsibility of the national authorities and is therefore 100 % financed by the country 
concerned.
However, the EMCDDA co -finances national focal points in EU Member States by means of an 
EC grant agreement which supports the implementation of specific activities in relation to national 
reporting functions and obligations in the EMCDDA’s annual work programme. 
Each NFP has to formally apply for a grant on a yearly basis. The EMCDDA grant agreements 
are fully in line with the rules and procedures used by the European Commission, and the NFPs 
are called upon to ensure adequate synergy with existing EC programmes to avoid overlap.
12. What is the ‘Reitox Academy’? 
The Reitox Academy is a training programme which addresses the training and information needs 
of the whole Reitox community, but also transfers knowledge and EMCDDA practices to  
candidate and potential candidate countries (1), the European Neighbourhood Policy countries 
(ENP) (2) and other third countries.
The Reitox Academy includes a wide array of courses and seminars on key EMCDDA technical 
tools and techniques. It aims to utilise the best expertise available in both the agency and 
Member States. It also addresses training needs related to setting up and developing national 
focal points and their expert networks.
Academies can be organised for a network of national or regional experts, for all Reitox 
members or for EU candidate, potential candidate and ENP countries. Occasionally and upon 
request, Reitox Academies are organised for third countries in the framework of EU -funded 
technical cooperation projects.
13. Who can benefit from Reitox national focal points’ expertise  
at national level and how?
Providing data on the drug situation at national level and also analysing how this is viewed in 
relation to the broader European and international contexts is one of the NFP’s functions. This 
means providing products for a range of audiences as follows:
•	 	Decision‑makers,	who	require	concise,	objective	information	in	order	to	make	the	relevant	
policy and budgetary decisions. This audience may also require information on current 
trends	in	drug	policies	across	Europe	to	feed	into	national	debate;	
•	 	Scientists	and	other	professionals	working	in	the	drugs	field	can	use	the	NFP	as	their	
information source on ongoing research and monitoring activities across the network and 
also as a link for cross-border cooperation, hence enhancing data collection practices 
across	Europe;
•	 	As	an	audience,	the	general	public	needs	broad	information	in	order	to	gain	insight	into	
changes	in	the	drug	situation	and	responses	at	national	and	European	level;
•	 	For	the	media,	focal	points	act	as	the	main	reference	point	on	the	drug	situation,	not	only	
in the country concerned, but also in Europe. The information provided to the media thus 
facilitates clear and factual reporting on the drugs situation.
(1)  Candidate and potential candidate countries are: Albania, Bosnia-Herzegovina, Croatia, Former Yugoslav 
Republic of Macedonia, Iceland, Kosovo under UN Security Council Resolution 1244/99, Montenegro, 
Serbia and Turkey.
(2)  European Neighbourhood Policy countries are: Algeria, Armenia, Azerbaijan, Belarus, Egypt, Georgia, 
Israel, Jordan, Lebanon, Libya, Moldova, Morocco, Occupied Palestinian Territories, Syria, Tunisia and 
Ukraine.
14. What is the added value in joining the Reitox network  
for non -EU countries?
Being involved in Reitox for non -EU countries brings first -hand experience of how drug 
monitoring systems operate in Europe, and at the same time broadens the view of Reitox 
members on the drug situation outside the EU. 
Whereas Reitox members participate in the European debate on drug data monitoring and 
reporting tools and processes, non -EU countries are invited to take part in selected training activities 
and technical expert meetings on a wide range of topics related to the EMCDDA’s areas of work.
By asking to join the Reitox network as explained in question 15, candidate and potential 
candidate countries are already fulfilling one of the requirements of the accession process. This 
is seen as a positive step in the process of aligning their respective national drug monitoring and 
reporting systems with the EU data collection processes. 
15. How can my country join the Reitox network? 
There are four different ways of taking part in the Reitox network:
•	 	By	becoming	a	member	of	the	EU:	at	the	end	of	the	accession	process,	new	EU	Member	
States automatically become members of the Reitox network, if they were not already 
members before.
•	 	By	preparing	for	EU	accession:	candidate	and	potential	candidate	countries	are	invited	to	
work with the EMCDDA and Reitox as part of the accession process. Technical cooperation 
activities are organised for these countries by the EMCDDA with the financial support of the 
Instrument for Pre-Accession (IPA), so that they can familiarise themselves with the work of a 
Reitox national focal point.
•	 	By	establishing	closer	ties	with	the	European	Union	in	the	case	of		neighbouring	countries:	
the European Neighbourhood Policy (ENP) foresees the possibility for partner countries 
to participate in the work of European agencies, including the EMCDDA and its Reitox 
network. The countries are invited to express their interest and priorities to the European 
Commission, as a prerequisite to benefitting from any technical cooperation with the 
EMCDDA.
•	 	By	applying	for	a	bilateral	agreement	to	develop	links	with	the	EMCDDA:	non‑EU	countries	
in general may participate in the work of the EMCDDA and the Reitox network on the basis 
of bilateral agreements negotiated with the European Commission on behalf of the European 
Union.
16. Where can I find the contact details for Reitox members?
All contact information on the current Reitox national focal points can be found at: 
http://www.emcdda.europa.eu/about/partners/reitox -network
Additional information:
On responsibilities of the Reitox national focal points in the EMCDDA, refer to the Recast 
Regulation (EC) No 1920/2006 of 12 December 2006:
http://www.emcdda.europa.eu/about
On the EU drugs strategy 2005–12: 
http://www.emcdda.europa.eu/policy-and-law/eu-activities
On data collection tools and reporting: 
http://www.emcdda.europa.eu 
On the organisation, operation and main functions of national drug observatories,  
see EMCDDA/CICAD–OAS, Building a national drugs observatory:  
a joint handbook, 2010. Available at: 
http://www.emcdda.europa.eu/publications/joint/ndo -handbook 
The publication is available in Arabic, Croatian, English, French, Italian, Russian, Spanish  
and Turkish.
On the European Neighbourhood Policy: 
http://ec.europa.eu/world/enp/index_en.htm
On the Instrument for Pre -accession Assistance: 
http://ec.europa.eu/enlargement/how -does -it -work/financial -assistance/ 
instrument -pre -accession_en.htm
For Frequently asked questions on the EU and the drugs phenomenon: 
http://www.emcdda.europa.eu/joint -publications/eu -faq
Available in English, French and Russian.
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